Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HRS 2017: EBR's Leadless CRT Feasibility; Watchman Registry Data; A Novel AF Ablation Catheter From BW; And More Medtronic CRT Data

Executive Summary

Results from "real-world" registries of established devices, along with encouraging early results from novel devices were among the highlights of Heart Rhythm 2017, the annual scientific sessions of the Heart Rhythm Society, held in Chicago May 10-13.

You may also be interested in...



January 2020 Approvals: Medtronic And Abbott Announce DBS Approvals

January’s new medical device approvals include the US FDA approval of a new indication for Abbott’s Infinity deep brain stimulation system and a CE mark for Abbott’s Tendyne transcatheter mitral valve replacement system. Medtronic also announced CE marks for a new line of implantable defibrillators and resynchronization devices as well as a CE mark for its Percept PC neurostimulator.

Starts & Stops: Mercator Looking To Leap Into New Indications For Bullfrog Micro-Infusion Drug-Delivery

Starts & Stops is a regular feature highlighting Medtech Insight's monthly editors' picks of noteworthy medtech clinical trial announcements, initiations, completions, and suspensions. This month's edition, covering November, is led by a major milestone for Mercator Medsystems, developer of the Bullfrog micro-infusion catheter.

HRS 2017: Medtronic And Boston Scientific's Less-Invasive CRM Devices Perform As Hoped In Real-World Registries

Results from the post-approval trials of Medtronic's Micra Transcatheter Pacing System and Boston Scientific's S-ICD presented at the Heart Rhythm Society Scientific Sessions in Chicago show these "leadless" devices can be implanted in "real world" patients with acute outcomes similar to those of the pre-market trials that had more restrictive inclusion criteria.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel